Lyell Immunopharma, Inc. (LYEL)
$7.51-9.19%Close
SELLCRISIS · day 26
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $184M
- Beta
- -0.07
- P/E (TTM)
- -0.47
- Short % float
- 8.64%
- Days to cover
- 7.4
- SI change
- +6.4%
- 1W
- -12.78%
- 1M
- -33.72%
- vs SPY 1W
- -12.64%
- vs SPY 1M
- -36.22%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 4
- GROWTH
- 2
- GARP
- 2
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-55.0%
REV YoY-
ROE-91.6%
EPS YoY-
ROA-79.9%
GROSS-8537
OP-711330
NET-920285
[VALUATION]
P/E TTM-0.47
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B0.75
P/FCF-
EV/EBITDA-0.62
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E15.80
ALTMAN Z-
CURR RATIO5.36
ND/EBITDA-
BETA-0.07
Company news
FAQ
- What is LOPJLB’s current signal on LYEL?
- LOPJLB’s latest quantitative signal on Lyell Immunopharma, Inc. (LYEL) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is LYEL in?
- Lyell Immunopharma, Inc. (LYEL) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Lyell Immunopharma, Inc. (LYEL) do?
- Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The companyâs lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and…